Abstract
This study establishes rates of Guillain-Barré syndrome relapse among Pfizer-BioNTech BNT162b2 vaccine receivers.
MeSH terms
- Adult
- BNT162 Vaccine
- COVID-19 Vaccines / adverse effects*
- Electronic Health Records
- Female
- Follow-Up Studies
- Guillain-Barre Syndrome / chemically induced*
- Guillain-Barre Syndrome / epidemiology
- Humans
- Israel / epidemiology
- Male
- Middle Aged
- Outcome Assessment, Health Care
- Recurrence
- Retrospective Studies
Substances
- COVID-19 Vaccines
- BNT162 Vaccine